Here’s a question to consider: are investors being blinded by artificial intelligence (AI), and missing huge money-making opportunities elsewhere? The answer is an emphatic yes. Case in point is the pharmaceutical sector. Of course, some pharma stocks have done extremely well. Especially those that repurposed the diabetes treatment GLP-1, unlocking a multi-billion dollar weight-loss industry. Investors piled into pharma stocks, taking the price-to-earnings ratio of the S&P 500 Healthcare Index, led by Eli Lilly (LLY), to its highest level in more than 20 years. Thanks to the ongoing shortages,…